Treatment evaluation of liraglutide in type 2 diabetes.

@article{Kela2012TreatmentEO,
  title={Treatment evaluation of liraglutide in type 2 diabetes.},
  author={Ram Kela and Melanie J Davies},
  journal={Expert opinion on biological therapy},
  year={2012},
  volume={12 11},
  pages={1551-6}
}
Liraglutide is a Glucagon like Peptide-1 (GLP-1) receptor agonist, which stimulates GLP-1 receptors and consequently leads to various cardio-metabolic and glycemic improvements in individuals with Type 2 Diabetes Mellitus (T2DM). It is administered once daily as a subcutaneous injection and has been extensively studied in randomized placebo and active comparator studies demonstrating favorable effects on glycemic control and weight reduction. This short review summarizes the role and practical… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Pharmacokinetics of liraglutide vs exenatide in type 2 diabetes: sustained vs fluctuating concentrations over 24 h. Diabetes 2009;58(Suppl 1):A150

  • J Rosenstock, J Gumprecht, E Szyprowska
  • 2009
Highly Influential
15 Excerpts

a retrospective observational pharmacy claims analysis

  • R Garg, W Chen, sitagliptin Pendergrass M. Acute pancreatitis in type 2 diabet or
  • Diabetes Care 2010; 33(11):2349-54 Affiliation…
  • 2012
1 Excerpt

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation

  • LB Knudsen, LW Madsen, S Andersen
  • Endocrinology
  • 2010
1 Excerpt

: sustained vs fluctuating concentrations over 24 h

  • T Vilsbøll, M Zdravkovic, T LeThi
  • 2009

Similar Papers

Loading similar papers…